Treatment of cutaneous leishmaniasis: Retrospectives and advances for the 21st century

Clinics in Dermatology

Volumn 17, Issue 3, 1999, Pages 305-315

  Moskowitz, Paula F ^a   Kurban, Amal K ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALLOPURINOL RIBOSIDE; ALPHA INTERFERON; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANNONA HAEMATANTHA EXTRACT; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; CLOTRIMAZOLE; DAPSONE; DIMETHYL SULFOXIDE; GAMMA INTERFERON; ITRACONAZOLE; KETOCONAZOLE; LIDOCAINE; LIQUID NITROGEN; MEGLUMINE ANTIMONATE; MICONAZOLE; NEOMYCIN; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE MESYLATE; QUINOLONE DERIVATIVE; SITAMAQUINE; STIBOGLUCONATE SODIUM; TERBINAFINE; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTHRALGIA; CRYOTHERAPY; DRUG EFFICACY; ELECTROSTIMULATION THERAPY; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEISHMANIA BRAZILIENSIS; LEISHMANIA MAJOR; LEISHMANIA PANAMENSIS; LEISHMANIA TROPICA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN IRRITATION; SKIN LEISHMANIASIS; TOPICAL DRUG ADMINISTRATION;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ANTIMONY; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIASIS, CUTANEOUS; RANDOMIZED CONTROLLED TRIALS;

EID: 0032705925     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(99)00049-8     Document Type: Review

References (111)

1. Neva F., Petersen E., Corsey R., et al. Observations on local heat treatment for cutaneous leishmaniasis. Am J Trop Med Hyg. 33:1984;800-804.
2. Junaid A. Treatment of cutaneous leishmaniasis with infrared heat. Int J Dermatol. 25:1986;470-472.
3. Aram H., Leibovici V. Ultrasound-induced hyperthermia in the treatment of cutaneous leishmaniasis. Cutis. 40:1987;350-353.
4. Levine N. Cutaneous leishmaniasis treated with controlled localized heating. Arch Dermatol. 128:1992;759-761.
5. Bassiouny A., El Meshad M., Talaat M., et al. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol. 107:1982;467-474.
6. Faber W. Cryosurgery for cutaneous leishmaniasis. J Dermatol Surg Oncol. 9:1983;354-356.
7. Azab A., Kamal M., El Haggar M., et al. Early surgical treatment of cutaneous leishmaniasis. J Dermatol Surg Oncol. 9:1983;1007-1012.
8. Leibovici V., Aram H. Cryotherapy in acute cutaneous leishmaniasis. Int J Dermatol. 25:1986;473-475.
9. Al-Gindan Y., Kubba R., Omer A., et al. Cryosurgery in Old World leishmaniasis. Br J Dermatol. 118:1988;851-854.
10. Sharquie K., al-Hamamy H., el-Yassin D. Treatment of cutaneous leishmaniasis by direct current electrotherapy The Baghdadin device . J Dermatol. 25:1998;234-237.
11. Berman J., Neva F. Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg. 30:1981;318-321.
12. Sacks D., Barral A., Neva F. Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro. Am J Trop Med Hyg. 32:1983;300-304.
13. El-On J., Greenblat C. An in vitro model for testing the effect of anti-leishmanial drugs of possible use in topical treatment. Curr Ther Res Clin Exp. 33:1983;660-669.
14. El-On J., Livshin R., Even-Paz Z., et al. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol. 87:1986;284-288.
15. El-On J., Halevy S., Grunwald M., Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major A double blind control study . J Am Acad Dermatol. 27:1992;227-231.
16. Ozgoztasi O., Baydar I. A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey. Int J Dermatol. 36:1997;61-63.
17. Bryceson A. Therapy in man. Peters W., Kilick-Kendrick R. The leishmaniasies in biology and medicine. vol. 2:1987;847-907 Academic Press, London.
18. Krause G., Kroeger A. Topical treatment of American cutaneous leishmaniasis with paromomycin and methylbenzethonium chloride A clinical study under field conditions in Ecuador . Trans R Soc Trop Med Hyg. 88:1994;92-94.
19. Soto J., Hernandez N., Mejia H., Grogl M., Berman J. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzathonium chloride and injectable meglumine antimonate. Clin Infect Dis. 20:1995;47-51.
20. Bryceson A., Murphy A., Moody A. Treatment of "Old World" cutaneous leishmaniasis with aminosidine ointment Results of an open study in London . Trans R Soc Trop Med Hyg. 88:1994;226-228.
21. El-Safi S., Murphy A., Bryceson A., Neal R. A double-blind clinical trial of the treatment of cutaneous leishmaniasis with paromomycin ointment. Trans R Soc Trop Med Hyg. 84:1990;690-691.
22. Asilian A., Jalayer T., Whitworth A., et al. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg. 53:1995;648-651.
23. Ben Salah A., Zakraoui H., Zaatour A., et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg. 1995;162-166.
24. Weinrauch L., Cawich F., Craig P., et al. Topical treatment of New World cutaneous leishmaniasis in Belize A clinical study . J Am Acad Dermatol. 29:1993;443-446.
25. Soto J., Fuya P., Herrera R., Berman J. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis Controlled study . Clin Infect Dis. 26:1998;56-58.
26. Ophir J., Krakowski A., Brenner S., et al. Miconazole treatment for cutaneous leishmaniasis. J Infect Dis. 148:1983;1168.
27. Brenner S. Topical treatment with imidazole for cutaneous leishmaniasis. Isr J Med Sci. 21:1985;163-164.
28. Dutz W., Agarval N., Bashardost M., et al. Topical therapy of cutaneous leishmaniasis with 2% ketoconazole ointment and DMSO [letter]. Int J Dermatol. 26:1987;199.
29. Abahusein A., Larbi E., Al-Khawajah A., et al. Evaluation of topical ketoconazole in cutaneous leishmaniasis. E Afr Med J. 69:1992;14-17.
30. Larbi E., Al-Khawajah A., Al-Gindan Y., et al. A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in the eastern province of Saudi Arabia. Am J Trop Med Hyg. 52:1995;166-168.
31. Berman J. Chemotherapy of leishmaniasis Biochemical mechanisms, clinical effficacy, and future strategies . Rev Infect Dis. 10:1988;560-586.
32. Kellum R. Treatment of cutaneous leishmaniasis with an intrelasional antimonial drug (pentostam). J Am Acad Dermatol. 15:1986;620-622.
33. Faris R., Jarallah J., Khoja T., Al-Yamani M. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol. 32:1993;610-612.
34. Alkhawajah A., Larbi E., al-Gindan Y., et al. Treatment of cutaneous leishmaniasis with antimony Intramuscular versus intralesional administration . Ann Trop Med Parasitol. 91:1997;899-905.
35. Tallab T., Bahamdam K., Mirdad S., et al. Cutaneous leishmaniasis Schedules for intralesional treatment with sodium stibogluconate . Int J Dermatol. 35:1996;594-597.
36. Sharquie K., Al-Talib K., Chu A. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol. 119:1988;53-57.
37. Harms G., Chehade A., Douba M., et al. A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-γ in the local treatment of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 85:1991;214-216.
38. Aste N., Pau M., Ferreli C., Biggio P. Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate. Br J Dermatol. 138:1998;370-371.
39. Belazzoug S., Neal R. Failure of meglumine antimoniate to cure cutaneous lesions due to Leishmania major in Algeria. Trans R Soc Trop Med Hyg. 80:1986;670-671.
40. El-Safi S., Peters W., El-Toam B., et al. Studies on the leishmaniases in the Sudan. 2. Clinical and parasitological studies on cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. 85:1991;457-464.
41. Mebrahtu Y., Lawyer P., Ngumbi P., et al. A new rural focus of cutaneous leishmaniasis caused by Leishmania tropica in Kenya. Trans R Soc Trop Med Hyg. 86:1992;381-387.
42. Ballou W., Gordon D., Andujar J., et al. Safety and efficacy of high-dose sodium stibogluconate therapy of American cutaneous leishmaniasis. Lancet. 2:1987;13-17.
43. Saenz R., Paz H., Berman J. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med. 89:1990;147-155.
44. Hepburn N., Tidman M., Hunter J. Cutaneous leishmaniasis in British troops from Belize. Br J Dermatol. 128:1993;63-68.
45. Hepburn N., Tidman M., Hunter J. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans Soc R Trop Med Hyg. 88:1994;700-703.
46. Navin T., Arana B., Arana F., et al. Placebo-controlled clinical trial of meglumine antimonate (Glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am J Trop Med Hyg. 42:1990;43-50.
47. Navin T., Arana B., Arana F., et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis. 165:1992;528-534.
48. Oliveira-Neto M., Schubach A., Mattos M., et al. Treatment of American cutaneous leishmaniasis A comparison between low dosage (5 mg/kg/day) and high dosage (20 mg/kg/day) antimony regimens . Pathol Biol. 45:1997;496-499.
49. Oliveira-Neto M., Schubach A., Mattos M., et al. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis Extensive follow-up studies (up to 10 years) . Am J Trop Med Hyg. 57:1997;651-655.
50. Arana B., Navin T., Arana F., et al. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-γ in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis. 18:1994;381-384.
51. Martinez S., Marr J. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med. 326:1992;741-743.
52. Martinez S., Gonzales M., Vernaza M. Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin Infect Dis. 24:1997;165-169.
53. Soto-Mancipe J., Grogl M., Berman J. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Columbia. Clin Infect Dis. 16:1993;417-425.
54. Velez I., Agudelo S., Hendrickx E., et al. Inefficacy of allopurinol as monotherapy for Columbian cutaneous leishmaniasis A randomized, controlled trial . Ann Intern Med. 126:1997;232-236.
55. Herwaldt B., Berman J. Recommendations for treating leishmaniasis with sodium stibogluconate (pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 46:1992;296-306.
56. Antezana G., Zeballos R., Mendoza C., et al. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimonate and allopurinol. Trans Soc R Trop Med Hyg. 86:1992;31-33.
57. Hepburn N., Siddique I., Howie A., et al. Hepatotoxicity of sodium stibogluconate in leishmaniasis. Lancet. 342:1993;238-239.
58. Gasser R. Jr, Magill A., Oster C., et al. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis. 18:1994;83-90.
59. Brummitt C., Porter J., Herwaldt B. Reversible peripheral neuropathy associated with sodium stibogluconate therapy for american cutaneous leishmaniasis. Clin Infect Dis. 22:1996;878-879.
60. Berman J., Gallalee J. Semiautomated assessment of in vitro activity of potential antileishmanial drugs. Antimicrob Agents Chemother. 28:1985;723-726.
61. Low-a-Chee R., Rose P., Ridley D. An outbreak of cutaneous leishmaniasis in Guyana Epidemiology, clinical and laboratory aspects . Ann Trop Med Parasitol. 77:1983;255-260.
62. Soto J., Buffet P., Grogl M., Berman J. Successful treatment of Columbian cutaneous leishmaniaisis with four injections of pentamidine. Am J Trop Med Hyg. 50:1994;107-111.
63. Chunge C., Owate J., Pamba H., Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg. 84:1990;221-225.
64. Scott J., Davidson R., Moody A., et al. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom. Trans R Soc Trop Med Hyg. 86:1992;617-619.
65. Thakur C., Olliaro P., Gothoskar S., et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (-paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg. 86:1992;615-616.
66. Soto J., Grogl M., Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Columbian cutaneous leishmaniasis. Trans Soc R Trop Med Hyg. 88:1994;695-698.
67. diMartino L., Raimondi F., Scotti S., et al. Efficacy and tolerability of liposomal amphotericin B in Italian infants with visceral leishmaniasis. Trans R Soc Trop Med Hyg. 87:1993;477.
68. Gokhale P., Kshirsagar N., Khan M., et al. Successful treatment of resistent visceral leishmaniasis with liposomal amphotericin B. Trans R Soc Trop Med Hyg. 88:1994;228.
69. Dietze R., Fagundes S., Brito E., et al. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg. 195:1995;309-311.
70. Seaman J., Boer C., Wilkinson R., et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis. 21:1995;188-193.
71. Davidson R., diMartino L., Gradoni L., et al. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis. 22:1996;938-943.
72. Sundar S., Murray H. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis. 173:1996;762-765.
73. Thakur C., Pandey A., Sinha G., et al. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India A randomized dose-finding study . Trans R Soc Trop Med Hyg. 90:1996;319-322.
74. Yardley V., Croft S. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother. 41:1997;752-756.
75. Panosian C., Barza M., Szaka F., Wyler D. Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 25:1984;655-656.
76. Torre-Cisneros J., Prada J., Villanuave J., et al. Successful treatment of antimony-resistant cutaneous leishmaniasis with liposomal amphotericin B. Clin Infect Dis. 18:1994;1024-1025.
77. Wortmann G., Fraser S., Aronson N., et al. Failure of amphoteracin B lipid complex in the treatment of cutaneous leishmaniasis. Clin Infect Dis. 26:1998;1006-1007.
78. Falcoff E., Taranto N., Remondegui C., et al. Clinical healing of antimony-resistent cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-γ and pentavalent antimony compounds. Trans R Soc Trop Med Hyg. 88:1994;95-97.
79. Kürkçüoglu N., Tandogdu R. Interferon gamma therapy for cutaneous leishmaniasis. Arch Dermatol. 126:1990;831-832.
80. Harms G., Zwingenberger K., Chehade A. Effects of intradermal gamma-interferon in cutaneous leishmaniasis. Lancet. 1:1989;1287-1292.
81. Baum K., Berens R. Successful treatment of cutaneous leishmaniasis with allopurinol after failure of treatment with ketoconazole. Clin Infect Dis. 18:1994;813-815.
82. Marsden P., Cuba C., Baretto A. Allopurinol treatment in human Leishmania braziliensis braziliensis infections. Trans Soc R Trop Med Hyg. 78:1984;419-420.
83. Saenz R., Paz H., Johnson C., et al. Treatment of American cutaneous leishmaniasis with orally administered allopurinal riboside. J Infect Dis. 160:1989;153-158.
84. Beach D., Goal L., Holz G.J. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol. 31:1988;149-162.
85. Gebre-Hiwot A., Frommel D. The in-vitro anti-leishmanial activity of inhibitors of ergosterol biosynthesis. J Antimicrob Chemother. 32:1993;837-842.
86. van Den Enden E., van Gompel A., Stevens A., et al. Treatment of cutaneous leishmaniasis with oral itraconazole. Int J Dermatol. 33:1994;285-286.
87. Dogra J., Aneja N., Lal B., Mishra S. Cutaneous leishmaniasis in India Clinical experience with itraconazole . Int J Dermatol. 29:1990;661-662.
88. Al-Fouzan A., Al-Saleh Q., Najem N., Rostom A. Cutaneous leishmaniasis in Kuwait Clinical experience with itraconazole . Int J Dermatol. 30:1991;419-421.
89. Akuffo H., Dietz M., Teklemariam S., et al. The use of itraconazole in the treatment of leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg. 84:1990;532-534.
90. Dogra J., Saxena V. Itraconazole and leishmaniasis A randomised double-blind trial in cutaneous disease . Int J Parasitol. 26:1996;1413-1415.
91. Momeni A., Jalayer T., Emamjomeh M., et al. Treatment of cutaneous leishmaniasis with itraconazole Randomized double-blind study . Arch Dermatol. 132:1996;784-786.
92. Weinrauch L., Livshin R., El-On J. Ketoconazole in cutaneous leishmaniasis. Br J Dermatol. 117:1987;666-667.
93. Norton M.S., Frakenburg S., Klaus S. Cutaneous leishmaniasis acquired during military service in the Middle East. Arch Dermatol. 128:1992;83-87.
94. Alsaleh Q., Dvorak R., Nanda A. Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait. Int J Dermatol. 34:1995;495-497.
95. Singh S., Singh R., Sundar S. Failure of ketoconazole treatment in cutaneous leishmaniasis. Int J Dermatol. 34:1995;120-121.
96. Urcuyo F., Zaias N. Oral ketoconazole in the treatment of leishmaniasis. Int J Dermatol. 21:1982;414-416.
97. Jolliffe D. Cutaneous leishmaniasis from Belize-treatment with ketoconazole. Clin Exp Dermatol. 11:1986;62-68.
98. Rangel H., Dager F., Hernandez A., et al. Naturaly azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine Comparative study with azole-susceptible Leishmania mexicana promastigotes . Antimicrob Agents Chemother. 40:1996;2785-2791.
99. Dogra J., Lal B., Misra S. Dapsone in the treatment of cutaneous leishmaniasis. Int J Dermatol. 25:1986;398-400.
100. Dogra J. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Trans Soc R Trop Med Hyg. 85:1991;212-213.
101. Osorio L., Palacios R., Chica M., Ochoa M. Treatment of cutaneous leishmaniasis in Colombia with dapsone. Lancet. 351:1998;498-499.
102. Fournet A., Vagneur B., Richomme P., Bruneton J. Aryl-2 et alkyl-2 quinoléines nouvelles isolées d'une Rutacée bolivienne Galipea longiflora . Can J Chem. 67:1989;2116-2118.
103. Fournet A., Barrios A., Muñoz V., et al. 2-Substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrob Agents Chemo. 37:1993;859-863.
104. Fournet A., Gantier J., Gautheret A., et al. The acyivity of 2-substituted quinoline alkaloids in BALB/c mice with Leishmania donovani. J Antimicrob Chemother. 33:1994;537-544.
105. Fournet A., Ferriera M., Rojas de Arias A., et al. In vivo efficacy of oral and intralesional administration of 2-substituted quinolines in experimental treatment of New World cutaneous leishmaniasis caused by Leishmania amazonensis. Antimicrob Agents Chemother. 40:1996;2447-2451.
106. Berman J., Lee L. Activity of 8-aminoquinolines against Leishmania tropica within human macrophages in vitro. Am J Trop Med Hyg. 32:1983;752-759.
107. Berman J., Lee L. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J Parasitol. 70:1984;220-225.
108. Neal R., Croft S. An in vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani. J Antimicrob Chemother. 14:1984;463-475.
109. Singh S., Sundar S., Singh V. Leishmaniasis Recent advances in treatment . J Am Acad Dermatol. 37:1997;512-513.
110. Waechter A., Ferreira M., Fournet A., et al. Experimental treatment of cutaneous leishmaniasis with argentilactone isolated from Annone haematantha. Planta Med. 63:1997;433-435.
111. Chan C., Yin H., Garforth J., et al. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. J Med Chem. 41:1998;148-156.